Close Menu

NEW YORK (GenomeWeb) – Taking stock of Myriad Genetics pipeline and recent stock performance, Cowen and Co. analyst Doug Schenkel today upgraded the company’s stock to an Outperform rating from a previous Market Perform rating.

"In our base case, we see a path to low-single digit to mid-single digit growth supporting multiple expansion and 15 percent to 20 percent upside from current levels without broader GeneSight reimbursement," Schenkel wrote in a note to investors. "The risk/reward is attractive."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.